Business
Video: The N.B.A. Returns to China After Six Years
new video loaded: The N.B.A. Returns to China After Six Years
transcript
transcript
The N.B.A. Returns to China After Six Years
The N.B.A, returns to China this week, after a hiatus sparked by a controversial 2019 tweet. In Macau, New York Times business reporter Tania Ganguli reveals the behind-the-scenes stakeholders who orchestrated the league’s return.
-
I’m in Macau, the gambling capital of the world. I’m here for the NBA’s return to China for the last six years, there haven’t been any NBA games here. looking at these big banners that are draped over buildings. Reminds me of being back here in 2019. the players were sitting in their hotel and they could see workers tearing those same types of banners down, peeling their faces off the building. A few days before, the Houston Rockets general manager, Daryl Morey, had sent a tweet in support of protesters in Hong Kong. Well, this made the Chinese government very upset. The NBA backed him. We are not apologizing for Daryl exercising his freedom of expression. And then chaos enveloped. That whole week. Sponsors pulled out. And a lot of the players were worried about if they would even be allowed to go home if things got worse. It was it was that surreal. they lost about $400 million. Just from that one situation The Chinese market is huge for the NBA. There are a lot of basketball fans here…. and the league has been working on cultivating them for decades. And so coming here to Macao and playing a game in China again is a very big deal for the league. when you ask anybody with the league how did these games come together? The name that they mentioned is Patrick Dumont. He’s a top executive with the Sands Casino. And owner of the Dallas Mavericks. in 2021, the Chinese government was renegotiating what’s called concessions with the casinos here in Macau. In those concession agreements, the government required that the casinos spend a certain amount on non-gaming activities like entertainment, like sports. And Sands had this arena at the Venetian, so Dumont saw bringing the NBA here as an opportunity to satisfy that requirement. One of the other main players here was Joe Sy, the owner of the Brooklyn Nets. Joe tsai is the chairman of Alibaba Group, which is a Chinese tech giant. he has a lot of deep ties to the Chinese government, the nets, and spent a lot of time over the last few years meeting with Chinese officials, having events that celebrate Chinese culture. they have spoken to Chinese media outlets and said, this market is so important to us. We care about this market more than any other NBA team. They even launched a reality show. That’s a dance team competition to choose dancers for their games here in Macao Sound up: “The brooklyn nets will find the best dancers in china” There’s a tremendous amount at stake for these teams because. The league saw what happened when something went wrong and they lost this market even briefly. there is a feeling that this has to go right, and that this is a big opportunity to get back something that they lost.
By Tania Ganguli, Christina Shaman, Kassie Bracken and Christina Thornell
October 11, 2025
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025.
Mike Blake | Reuters
Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, building on efforts by the company and the Trump administration to make the medicine more accessible.
The announcement also comes weeks after chief rival Novo Nordisk unveiled additional discounts on the cash prices of its obesity and diabetes drugs.
Starting Monday, cash-paying patients with a valid prescription can get the starting dose of Zepbound vials for as low as $299 per month on LillyDirect, down from a previous price of $349 per month. They can also access the next dose, 5 milligrams, for $399 per month and all other doses for $449 per month, down from $499 per month across those sizes.
Zepbound carries a list price of roughly $1,086 per month. That price point, and spotty insurance coverage for weight loss drugs in the U.S., have been significant barriers to access for some patients.
Eli Lilly’s announcement comes just weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to get and afford. The agreements will cut the prices the government pays for the drugs, introduce Medicare coverage of obesity drugs for the first time for certain patients and offer discounted medicines on the government’s new direct-to-consumer website launching in January, TrumpRx.
But Eli Lilly’s deal with Trump centers around lowering the prices of a different form of Zepbound – a multi-dose pen – after it wins Food and Drug Administration approval.
That means Eli Lilly’s Monday announcement around cutting prices on the existing single-dose vials could allow more patients to get discounted treatments more quickly.
“We will keep working to provide more options — expanding choices for delivery devices and creating new pathways for access — so more people can get the medicines they need,” said Ilya Yuffa, president of Lilly USA and global customer capabilities, in a statement.
Eli Lilly’s stock, which has climbed more than 36% this year, fell nearly 2% on Monday. Its meteoric rise due to the success of Zepbound and its diabetes injection Mounjaro vaulted it to becoming the first health-care company to hit a $1 trillion market value last month. Though cutting prices means lower revenue per medication sold, Eli Lilly’s sales — and shares — have continued to soar through past pricing announcements as demand balloons.
With single-dose vials, patients need to use a syringe and needle to draw up the medicine and inject it into themselves. Eli Lilly first introduced that form of Zepbound in August 2024.
It’s unclear how many patients are currently using single-dose vials of Zepbound. But Eli Lilly previously said that direct-to-consumer sales now account for more than a third of new prescriptions of Zepbound.
Novo Nordisk earlier this month lowered the price of its obesity drug Wegovy and diabetes treatment Ozempic for existing cash-paying patients to $349 per month from $499 per month. That excludes the highest dose of Ozempic.
The company also launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment.
The Oil and Gas Regulatory Authority (OGRA) has approved a fresh increase in the price of liquefied petroleum gas (LPG), raising the cost for both domestic consumers and commercial users.
According to the notification issued, the LPG price has been increased by Rs7.39 per kilogram, setting the new rate at Rs209 per kg for December. As a result, the price of a domestic LPG cylinder has risen by Rs87.21, bringing the new price to Rs2,466.10.
In November, the price of LPG stood at Rs201 per kg, while the domestic cylinder was priced at Rs2,378.89.
The latest price hike is expected to put additional pressure on households already grappling with rising living costs nationwide.
New Delhi: The taxable value of all supplies under GST surged by a robust 15 per cent during September-October this year, compared to the same period in 2024 due to sharp increase in consumption triggered by the tax rate cuts on goods across sectors that kicked in from September 22, according to official sources.
The growth in the same two-month period last year was 8.6 per cent. “This surge in taxable value during ‘Bachat Utsav’ demonstrates strong consumption uplift, stimulated by reduced rates and improved compliance behaviour,” a senior official said.
He pointed out that the growth has especially been strong in sectors where rate rationalisation was implemented, such as FMCG, pharma goods, food products, automobiles, medical devices and textiles. In these sectors, the taxable value of supplies has seen significantly higher growth, confirming that lower GST rates translated directly into higher consumer spending.
“It vindicates our strategy that reducing rates on essentials and mass-use sectors would create demand-side buoyancy — a Laffer Curve–type demand uplift,” he explained.These trends confirm that GST next-gen reforms have not disrupted revenue stability, and that consumption-side buoyancy has begun to translate into higher taxable value in key sectors.
This growth is in value terms which means that since GST rates were lower, the growth in volume terms will be even higher. It is clearly visible that while the Next Gen Reforms resulted in significant Bachat — increased consumption, industry has been very proactive in passing on the GST savings to the final consumers and ensuring that there is no supply side deficiency.
As GDP private consumption data will be released much later, GST taxable value serves as the most reliable real-time proxy for consumption, and the current numbers clearly indicate sustained demand expansion, the official added.
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
Geoffrey Boycott advises England to ‘use brains’ for Ashes remainder
Wake Up—the Best Cyber Monday Mattress and Bedding Sales Are Here
-
Sports1 week agoWATCH: Ronaldo scores spectacular bicycle kick
-
Entertainment1 week agoWelcome to Derry’ episode 5 delivers shocking twist
-
Politics1 week agoWashington and Kyiv Stress Any Peace Deal Must Fully Respect Ukraine’s Sovereignty
-
Business1 week agoKey economic data and trends that will shape Rachel Reeves’ Budget
-
Tech6 days agoWake Up—the Best Black Friday Mattress Sales Are Here
-
Politics1 week ago53,000 Sikhs vote in Ottawa Khalistan Referendum amid Carney-Modi trade talks scrutiny
-
Fashion1 week agoCanada’s Lululemon unveils team Canada kit for Milano Cortina 2026
-
Tech1 day agoGet Your Steps In From Your Home Office With This Walking Pad—On Sale This Week